HR Execs on the Move

PACT Pharma

www.pactpharma.com

 
PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.pactpharma.com
  • 2 Corporate Drive
    South San Francisco, CA USA 94080
  • Phone: 650.597.9500

Executives

Name Title Contact Details
Jeroen Grasman
Chief Financial Officer Profile
Robin Cartwright
Head of Talent Acquisition Profile

Similar Companies

Kiwa Bio-Tech Products Group Corporation

Kiwa Bio-Tech Products Group Corporation is a Claremont, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Santaris Pharma A/S USA

Santaris Pharma A/S USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharma Test-Americas

Pharma Test-Americas is a Markham, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Goodness Growth

Goodness Growth Holdings, Inc. is a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. Today, the Company is licensed to grow, process, and/or distribute cannabis in four markets and operates 14 dispensaries in three states.

Phathom Pharmaceuticals

Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.